physIQ

physIQ develops an advanced digital health platform that specializes in continuous physiological monitoring. Leveraging artificial intelligence and proprietary analytics, the platform processes real-time data collected from wearable biosensors. This technology establishes personalized baselines for individuals, enabling the early detection of subtle, clinically relevant changes in patient health, thereby predicting potential decompensation or complications across various disease states. The solution is device-agnostic and offers FDA-cleared personalized analytics for comprehensive insights.

The company was founded in 2013 by Gary Conkright, a Purdue alumnus, and is based in Chicago. Conkright's foundational insight stemmed from the potential to apply sophisticated artificial intelligence models to continuous, high-fidelity physiological data streamed from wearable sensors. This approach aimed to generate unprecedented, individualized health insights, moving beyond episodic measurements to fundamentally improve patient outcomes and proactive care management.

physIQ’s platform is utilized by healthcare providers, life sciences organizations, and researchers, primarily supporting remote patient monitoring initiatives and enhancing the efficiency of pharmaceutical clinical trials. The company’s vision is to empower clinicians and research professionals with dynamic, personalized health intelligence, facilitating smarter and faster decision-making. physIQ ultimately seeks to modernize medical research and significantly elevate the standard of patient care through its innovative AI-powered digital medicine approach.

High-Level Overview

physIQ is a Chicago-based digital medicine company that builds an enterprise-ready cloud platform for personalized physiology data analytics, using continuous data from wearable biosensors and FDA-cleared AI algorithms to detect clinically meaningful changes against an individual's baseline rather than population norms.[1][2][3] It serves healthcare providers, health systems, payers, life sciences companies, and clinical trial sponsors by enabling remote patient monitoring, predicting decompensation across disease states, and accelerating drug development through real-world data insights.[1][4][5] The platform solves the problem of reactive care by providing proactive, actionable health insights—such as early detection of complications in post-acute care, Hospital-at-Home programs, and COVID-19 monitoring—transforming physiological data into personalized biomarkers for better outcomes and faster interventions.[2][5][6]

With nearly three million hours of curated patient data backing its analytics, physIQ has demonstrated growth through rigorous clinical studies, FDA clearances, partnerships (e.g., UI Health, Department of Defense, Duke University), and applications in virtual care models, positioning it as a pioneer in AI-driven digital health.[1][2][6][7]

Origin Story

physIQ emerged from technology originally developed at Argonne National Laboratory for monitoring mission-critical industrial assets like nuclear power plants and jet engines.[2][3] In 1999, CEO Gary Conkright co-founded SmartSignal with the University of Chicago to commercialize this machine learning tech, which became the gold standard for asset health monitoring and was later acquired by GE.[3] Motivated by a family member's chronic illness and the success of applying the tech to "the most important machine—the human body," Conkright spun out physIQ around 2014 with co-founders Stephan Wegerich (original inventor from Argonne) and Matt Pipke.[2][3]

The idea crystallized through collaborations with medical researchers from The University of Chicago Medical Center and other hospitals, proving the tech's efficacy for human physiology via personalized baselines for vital signs like heart rate, respiration, blood pressure, and oxygen levels.[3] Early traction came from validating AI analytics in clinical studies, securing FDA clearances, and deploying in real-world scenarios, evolving from industrial roots to a medical-grade platform compatible with any wearable sensor.[1][2]

Core Differentiators

• Personalized AI Analytics: Unlike population-norm tools, physIQ establishes an individual baseline using machine learning, enabling higher sensitivity to subtle changes and FDA-cleared biomarkers for predicting decompensation across diseases.[1][3][5]
• Sensor-Agnostic Platform: Enterprise cloud system processes data from any wearable biosensor, supporting continuous streaming, patient-reported outcomes (ePROMs), and diverse use cases like remote monitoring and clinical trials.[2][4][5]
• Regulatory and Clinical Rigor: Pioneers in AI validation with one of digital medicine's most rigorous studies, multiple FDA clearances, and nearly three million hours of curated data; HIPAA-compliant for healthcare and life sciences.[1][5][6]
• Clinician-Centric Tools: Dashboards deliver real-time health status indices, alerts for early intervention, and scalability for post-acute care, Hospital-at-Home, and high-risk monitoring (e.g., COVID-19).[5][6]
• Proven Scalability: Deployed in partnerships like UI Health for frontline workers/patients and DoD/Duke studies, with applications accelerating drug trials and proactive care.[6][7]

Role in the Broader Tech Landscape

physIQ rides the wave of digital therapeutics and remote patient monitoring (RPM), fueled by post-COVID demand for virtual care, wearable proliferation, and AI regulatory momentum, enabling a shift from reactive to predictive healthcare.[1][5][6] Timing aligns with market forces like aging populations, chronic disease burdens, payer incentives for early intervention (e.g., Blue Cross pilots), and life sciences' need for real-world evidence to speed trials.[2][4][5]

It influences the ecosystem by democratizing AI analytics—compatible with any sensor/data type—lowering barriers for health systems and pharma to adopt scalable RPM, reducing hospitalizations, and addressing disparities in underserved communities via contactless deployments.[3][6] As a bridge from industrial AI to human physiology, physIQ accelerates digital medicine's maturity, validating tech for complex biological "machines" amid rising biosensor adoption.[2][3]

Quick Take & Future Outlook

physIQ is poised to expand as RPM and AI biomarkers become standard in value-based care, with potential growth in Hospital-at-Home scaling, global clinical trials, and integrations with emerging wearables/multi-omics data. Trends like FDA's AI/ML frameworks and payer reimbursements will amplify its edge, while partnerships could drive acquisitions by big pharma or tech giants seeking real-world data platforms. Its influence may evolve from pioneer to infrastructure layer, powering personalized medicine and tying back to its core mission: intelligence for the human machine, enabling earlier saves and faster therapies.[1][2]